VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platformSOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) Verge Genomics, a leading clinical-stage biotechnology company, and Ferrer, an international B Corp pharmaceutical company with an increasing focus in rare neurological disorders, have announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the tr
Amylyx Pharmaceuticals, Inc. today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide , AMX0114, for the potential.